Early Versus Delayed Closure of Bladder Exstrophy in Female Patients
Primary Single-Stage Early Versus Delayed Closure of Bladder Exstrophy in Female Patients: A Randomized Controlled Trial
調査の概要
詳細な説明
Eligible phenotypic female neonates who presented with classic bladder exstrophy within the first 48 hours of life and met the prespecified clinical and anaesthetic criteria were enrolled through consecutive sampling. After written consent and baseline assessment, participants were randomized in a 1:1 ratio using a computer-generated sequence with randomly varying block sizes and stratification by centre. Allocation was implemented through sequentially numbered sealed envelopes prepared independently of recruitment.
Participants assigned to early closure underwent primary single-stage repair within 72 hours of birth. Participants assigned to delayed closure underwent the same repair at 6 to 12 weeks of age. Before delayed surgery, the exposed bladder plate was cleaned with sterile saline and covered with a clear non-adherent pad, while hydration and weight gain were monitored. The operation included closure of the bladder and posterior urethra and reconstruction of the lower abdominal wall, pelvic floor, and female external genitalia. Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension. Perioperative care was standardized in both groups.
Participants were assessed on postoperative days 7, 14, and 30. Successful bladder closure on postoperative day 30 required an intact deep bladder and abdominal-wall closure without full-thickness wound dehiscence, urinary fistula, or urinary leakage requiring repeat closure or urinary diversion. Secondary outcomes were wound dehiscence, surgical-site infection, urinary fistula, blood transfusion, reoperation, readmission, hospital stay, and adverse events. The primary analysis followed the intention-to-treat principle.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Khyber Pakhtunkhwa
-
Peshawar、Khyber Pakhtunkhwa、パキスタン
- Khyber Teaching Hospital
-
-
参加基準
適格基準
就学可能な年齢
- 子
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Phenotypic female neonates presenting with classic bladder exstrophy within the first 48 hours of life
- Met the protocol-defined minimum birth-weight requirement
- Gestational age of at least 34 weeks
- Clinically stable and fit for general anaesthesia
- Written informed consent provided by a parent or legal guardian
Exclusion Criteria:
- Cloacal exstrophy, an exstrophy variant, or isolated epispadias
- Previous bladder or abdominal-wall surgery
- Life-threatening congenital anomaly
- Uncontrolled sepsis
- Coagulopathy
- Cardiorespiratory instability precluding surgery within the assigned window
- Parent or legal guardian unable or unwilling to comply with follow-up
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Early Closure
Participants underwent primary single-stage closure within 72 hours of birth.
|
Primary single-stage closure performed within 72 hours of birth.
The procedure included closure of the bladder and posterior urethra and reconstruction of the lower abdominal wall, pelvic floor, and female external genitalia during one anaesthetic.
Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension.
|
|
アクティブコンパレータ:Delayed Closure
Participants underwent primary single-stage closure at 6 to 12 weeks of age.
|
Primary single-stage closure performed at 6 to 12 weeks of age using the same operative checklist and repair.
Before surgery, the exposed bladder plate was cleaned with sterile saline and covered with a clear non-adherent pad, with monitoring of hydration and weight gain.
Pelvic osteotomy was reserved for predefined anatomical findings or excessive closure tension.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Successful Bladder Closure at Postoperative Day 30
時間枠:Postoperative day 30
|
Number and percentage of participants with an intact deep bladder and abdominal-wall closure without full-thickness abdominal wound dehiscence, urinary fistula, or urinary leakage requiring repeat closure or urinary diversion on or before postoperative day 30.
|
Postoperative day 30
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Wound Dehiscence Within 30 Days
時間枠:From surgery through postoperative day 30
|
Number and percentage of participants with partial or complete, superficial or deep disruption of the operative wound within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Surgical-Site Infection Within 30 Days
時間枠:From surgery through postoperative day 30
|
Number and percentage of participants with inflammatory signs at the operative site, with or without purulent discharge or positive culture, requiring antibiotic or surgical treatment within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Urinary Fistula Within 30 Days
時間枠:From surgery through postoperative day 30
|
Number and percentage of participants with continuous urinary leakage from the wound or another site after surgery, confirmed clinically or by imaging and requiring continued drainage or intervention.
|
From surgery through postoperative day 30
|
|
Blood Transfusion
時間枠:From the start of surgery through hospital discharge, up to 30 days after surgery
|
Number and percentage of participants who received a blood transfusion during the operative or perioperative period.
|
From the start of surgery through hospital discharge, up to 30 days after surgery
|
|
Reoperation Within 30 Days
時間枠:From surgery through postoperative day 30
|
Number and percentage of participants who underwent a repeat surgical procedure related to the primary closure within 30 days after surgery.
|
From surgery through postoperative day 30
|
|
Readmission Within 30 Days
時間枠:From discharge through postoperative day 30
|
Number and percentage of participants readmitted to hospital within 30 days after surgery.
|
From discharge through postoperative day 30
|
|
Hospital Stay
時間枠:From surgery to hospital discharge, up to 30 days after surgery
|
Duration of the index postoperative hospital stay, measured in days from surgery to discharge.
|
From surgery to hospital discharge, up to 30 days after surgery
|
|
Any Adverse Event Within 30 Days
時間枠:From surgery through postoperative day 30
|
Number and percentage of participants with at least one recorded adverse event within 30 days after surgery.
|
From surgery through postoperative day 30
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- KTH-BE-RCT-2021-2026
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。